NASDAQ:NXTC

NextCure - NXTC Stock Forecast, Price & News

$5.19

+0.10 (+1.96%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.01
▼
$5.20
50-Day Range: $4.21
▼
$5.09
52-Week Range: $3.25
▼
$9.18

Volume: 103,812 shs
Average Volume: 152,868 shs
Market Capitalization: $144.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

NextCure MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 189.0% Upside
$15.00 Price Target
Short Interest: Healthy
4.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: 1.50
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.55) to ($2.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

298th out of 1,125 stocks

Pharmaceutical Preparations Industry

145th out of 554 stocks

3.4

Analyst's Opinion

Consensus Rating
NextCure has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, NextCure has a forecasted upside of 189.0% from its current price of $5.19.
Amount of Analyst Coverage
NextCure has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.40% of the float of NextCure has been sold short.
Short Interest Ratio / Days to Cover
NextCure has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in NextCure has recently decreased by 9.36%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NextCure does not currently pay a dividend.
Dividend Growth
NextCure does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
NextCure has received a 73.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for NextCure is -0.77.

3.1

News and Social Media Coverage

News Sentiment
NextCure has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for NextCure this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NextCure insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.80% of the stock of NextCure is held by insiders.
Percentage Held by Institutions
51.83% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NextCure are expected to decrease in the coming year, from ($2.55) to ($2.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NextCure is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NextCure is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NextCure has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NextCure (NASDAQ:NXTC) Stock

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure Stock Performance

Shares of NXTC opened at $5.09 on Monday. The firm has a market capitalization of $141.23 million, a price-to-earnings ratio of -1.92 and a beta of -0.10. NextCure has a one year low of $3.25 and a one year high of $9.18. The stock's fifty day moving average is $4.60 and its 200-day moving average is $4.65.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their target price on NextCure from $21.00 to $13.00 and set an "overweight" rating on the stock in a research note on Monday, May 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

August 7, 2022 | seekingalpha.com

NextCure (NXTC) Investor Presentation - Slideshow

August 4, 2022 | seekingalpha.com

NextCure GAAP EPS of -$0.65 beats by $0.09 (NASDAQ:NXTC) - Seeking Alpha

August 15, 2022 | UNKNOWN (Ad)

New $2.2 Quadrillion Trend About To Open Up

Massive Opportunities For Investors

August 4, 2022 | finance.yahoo.com

NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

August 3, 2022 | streetinsider.com

Cape Fox Corporation is Leading the Way With a New Innovation Hub - StreetInsider.com

July 6, 2022 | finance.yahoo.com

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

June 27, 2022 | finance.yahoo.com

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM - Yahoo Finance

June 27, 2022 | finance.yahoo.com

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

August 15, 2022 | Weiss Ratings (Ad)

The Fed Can't Save Us This Time

The American economy is crumbling, and there's NOTHING Fed Chair Jerome Powell can do to stop it. Today, Dr. Martin Weiss reveals 7 simple steps you can take to protect your wealth from the biggest crisis of our lifetimes. Take action now before it's too late.

June 25, 2022 | finance.yahoo.com

We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely

June 22, 2022 | finance.yahoo.com

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting

May 31, 2022 | benzinga.com

NextCure (NASDAQ:NXTC), Short Interest Report

May 31, 2022 | benzinga.com

NextCure (NASDAQ:NXTC), Analyst Ratings, Price Targets, Predictions

May 24, 2022 | benzinga.com

Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $13 - Benzinga - Benzinga

May 23, 2022 | seekingalpha.com

CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space - Seeking Alpha

May 11, 2022 | finance.yahoo.com

NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price - Yahoo Finance

May 11, 2022 | finance.yahoo.com

NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price

May 5, 2022 | finance.yahoo.com

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results - Yahoo Finance

May 5, 2022 | finance.yahoo.com

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

May 3, 2022 | finance.yahoo.com

NextCure to Present at the BofA Securities 2022 Healthcare Conference

May 3, 2022 | benzinga.com

NextCure to Present at the BofA Securities 2022 Healthcare Conference - Benzinga - Benzinga

April 19, 2022 | globenewswire.com

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation - GlobeNewswire

April 19, 2022 | finance.yahoo.com

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

April 17, 2022 | greenwichtime.com

New program changes how Yale turns ideas into business ventures - Greenwich Time

April 5, 2022 | finance.yahoo.com

NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

March 17, 2022 | finance.yahoo.com

What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? - Yahoo Finance

March 15, 2022 | finance.yahoo.com

What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Company Calendar

Last Earnings: 11/04/2021
Today: 8/15/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NXTC
CUSIP: N/A
CIK: 1661059
Web: www.nextcure.com
Phone: (240) 399-4900
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +189.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,390,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.85%
Return on Assets: -31.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 33.87
Quick Ratio: 33.87

Sales & Book Value

Annual Sales: $22.38 million
Price / Sales: 6.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.45 per share
Price / Book: 0.61

Miscellaneous

Outstanding Shares: 27,747,000
Free Float: 25,305,000
Market Cap: $144.01 million
Optionable: Not Optionable
Beta: -0.10

Key Executives

Mr. Michael S. Richman MSBA (Age 61)
Co-Founder, CEO, Pres & Director
Comp: $726.42k
Dr. Solomon Langermann Ph.D. (Age 62)
Chief Scientific Officer
Comp: $527.98k
Dr. Han Myint FACP (Age 69)
M.D., Chief Medical Officer
Comp: $611.98k
Dr. Lieping Chen M.D. (Age 64)
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Mr. Steven P. Cobourn CPA (Age 59)
CPA, Chief Financial Officer
Dr. Timothy Mayer Ph.D. (Age 57)
Chief Operating Officer
Mr. Sourav Kundu Ph.D. (Age 62)
Sr. VP of Devel. & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NXTC Stock - Frequently Asked Questions

Should I buy or sell NextCure stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings or view top-rated stocks.
What is NextCure's stock price forecast for 2022?: 5 brokerages have issued twelve-month target prices for NextCure's shares. Their NXTC share price forecasts range from $13.00 to $17.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 191.8% from the stock's current price.
View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts.
How have NXTC shares performed in 2022?: NextCure's stock was trading at $6.00 at the start of the year. Since then, NXTC stock has decreased by 14.3% and is now trading at $5.14.
View the best growth stocks for 2022 here.
When is NextCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NXTC earnings forecast.
How were NextCure's earnings last quarter?: NextCure, Inc. (NASDAQ:NXTC) issued its earnings results on Thursday, November, 4th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.02.
What other stocks do shareholders of NextCure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?: (NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.
What is NextCure's stock symbol?: NextCure trades on the NASDAQ under the ticker symbol "NXTC."
Who are NextCure's major shareholders?: NextCure's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (1.21%), Renaissance Technologies LLC (1.05%), Assenagon Asset Management S.A. (0.39%), Ikarian Capital LLC (0.26%), Connor Clark & Lunn Investment Management Ltd. (0.24%) and JPMorgan Chase & Co. (0.12%).
View institutional ownership trends.
How do I buy shares of NextCure?: Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NextCure's stock price today?: One share of NXTC stock can currently be purchased for approximately $5.14.
How much money does NextCure make?: NextCure (NASDAQ:NXTC) has a market capitalization of $142.62 million and generates $22.38 million in revenue each year. The company earns $-69,390,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.
How can I contact NextCure?: NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The official website for the company is www.nextcure.com. The company can be reached via phone at (240) 399-4900 or via email at ir@nextcure.com.

This page (NASDAQ:NXTC) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NextCure - NXTC Stock Forecast, Price & News

NextCure MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month